Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.10 EUR | +0.46% |
|
-3.16% | +21.05% |
Feb. 17 | CARL ZEISS MEDITEC AG : UBS remains Neutral | ZD |
Feb. 14 | CARL ZEISS MEDITEC AG : Gets a Neutral rating from RBC | ZD |
Capitalization | 4.82B 5.05B 4.55B 4.01B 7.17B 439B 7.94B 54.07B 20.05B 183B 18.94B 18.57B 765B | P/E ratio 2025 * |
28.9x | P/E ratio 2026 * | 23.3x |
---|---|---|---|---|---|
Enterprise value | 5.24B 5.49B 4.94B 4.35B 7.78B 476B 8.62B 58.7B 21.76B 199B 20.56B 20.15B 831B | EV / Sales 2025 * |
2.4x | EV / Sales 2026 * | 2.2x |
Free-Float |
40.86% | Yield 2025 * |
1.24% | Yield 2026 * | 1.48% |
Last Transcript: Carl Zeiss Meditec AG
1 day | +0.46% | ||
1 week | -3.16% | ||
Current month | -6.69% | ||
1 month | +22.72% | ||
3 months | -6.21% | ||
6 months | -11.34% | ||
Current year | +21.05% |







Manager | Title | Age | Since |
---|---|---|---|
Markus Weber
CEO | Chief Executive Officer | 52 | 2021-12-30 |
Director of Finance/CFO | 59 | 2018-09-30 | |
Chief Operating Officer | 46 | - |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 2018-04-09 | |
Karl Lamprecht
CHM | Chairman | 61 | 2021-05-26 |
Isabel de Paoli
BRD | Director/Board Member | 51 | 2020-06-24 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+0.46% | -3.16% | -50.25% | -58.21% | 5.04B | ||
+0.70% | +2.16% | +57.29% | +104.56% | 212B | ||
-0.15% | -6.93% | -2.92% | -3.36% | 203B | ||
-0.03% | +0.82% | +61.21% | +140.12% | 156B | ||
+1.33% | -0.22% | -17.48% | -22.93% | 148B | ||
+0.21% | +2.13% | +6.89% | +3.72% | 67.37B | ||
+0.25% | +8.30% | -11.51% | -31.15% | 44.94B | ||
-0.53% | +4.58% | -15.60% | -15.35% | 43.65B | ||
-1.36% | +5.21% | +7.20% | - | 42.17B | ||
-1.30% | -7.26% | -0.13% | -0.36% | 38.42B | ||
Average | -0.04% | +0.03% | +3.47% | +13.01% | 96.22B | |
Weighted average by Cap. | +0.22% | -0.45% | +18.57% | +41.21% |
2025 * | 2026 * | |
---|---|---|
Net sales | 2.18B 2.29B 2.06B 1.81B 3.25B 199B 3.59B 24.48B 9.08B 82.94B 8.58B 8.41B 346B | 2.34B 2.45B 2.21B 1.94B 3.47B 213B 3.85B 26.21B 9.72B 88.79B 9.18B 9B 371B |
Net income | 152M 159M 143M 126M 225M 13.79B 249M 1.7B 630M 5.75B 595M 583M 24.04B | 201M 211M 190M 167M 299M 18.31B 331M 2.26B 836M 7.64B 790M 774M 31.92B |
Net Debt | 413M 432M 390M 343M 613M 37.56B 679M 4.63B 1.72B 15.67B 1.62B 1.59B 65.48B | 322M 338M 304M 268M 479M 29.34B 531M 3.61B 1.34B 12.24B 1.27B 1.24B 51.15B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-17 | 55.10 € | +0.46% | 178,082 |
25-02-14 | 54.85 € | -0.09% | 241,302 |
25-02-13 | 54.90 € | +7.23% | 452,996 |
25-02-12 | 51.20 € | -12.48% | 808,562 |
25-02-11 | 58.50 € | +2.09% | 191,258 |
Delayed Quote Xetra, February 17, 2025 at 11:35 am EST
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AFX Stock